This phase II trial studies the side effects and how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed state I-II nasal natural killer (NK) cell lymphoma. Drugs used in chemotherapy, such as dexamethasone, etoposide, ifosfamide, and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill cancer cells and shrink tumors. Giving more than one drug (combination chemotherapy) with radiation therapy may kill more cancer cells.
Additional locations may be listed on ClinicalTrials.gov for NCT02106988.
Locations matching your search criteria
United States
Texas
Houston
M D Anderson Cancer CenterStatus: Active
Contact: Bouthaina Shbib Dabaja
Phone: 713-563-2300
PRIMARY OBJECTIVES:
I. To measure the progression-free survival in newly diagnosed patients with stage I/II NK cell lymphoma-nasal type when treated with concurrent chemotherapy and radiation.
II. To evaluate and document the toxicity and efficacy of this approach.
SECONDARY OBJECTIVE:
I. To evaluate the overall survival after successful completion of concurrent chemotherapy with 3 cycles of dexamethasone, etoposide, ifosfamide, and carboplatin (DeVIC) and radiation therapy.
OUTLINE:
Patients undergo radiation therapy 5 days a week for 28-30 treatments (up to 6 weeks). Within 7 days of starting radiotherapy, patients receive dexamethasone intravenously (IV) over 15 minutes, etoposide IV over 2 hours, and ifosfamide IV over 3 hours on days 1-3 and carboplatin IV over 30 minutes on day 1. Chemotherapy repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorBouthaina Shbib Dabaja
